Drugs / PegIFN
PegIFN
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01095835 | Feb 2005 → Jan 2010 | chronic hepatitis B virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEG-IFN | “Treatment with peginterferon α-2a (PegIFN) for 48 weeks is the standard of care for selected HBeAg-negative patients chronically infected with hepatitis B virus (HBV), but with...” PMID 22859496 ↗ Aug 20121“Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg” NCT01095835 ↗ |
| Known as | peginterferon α-2a | “Treatment with peginterferon α-2a (PegIFN) for 48 weeks is the standard of care for selected HBeAg-negative patients chronically infected with hepatitis B virus (HBV), but with...” PMID 22859496 ↗ Aug 2012 |
| Known as | Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01095835 ↗ |
| Route | Subcutaneous | “PEG-IFN alfa-2a 180 micrograms (mcg) was administered subcutaneously, once weekly from Week 0 to 48.” NCT01095835 ↗ |